CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. - Wikidata - wikimedia - TriplyDB

CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance.

CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance.

http://www.wikidata.org/entity/Q46828201

about

Lipid-Induced Insulin Resistance in Skeletal Muscle: The Chase for the Culprit Goes from Total Intramuscular Fat to Lipid Intermediates, and Finally to Species of Lipid Intermediates Sphingolipids in High Fat Diet and Obesity-Related Diseases From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism Lipidomics-Reshaping the Analysis and Perception of Type 2 Diabetes Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis Imaging Mass Spectrometry Reveals Acyl-Chain- and Region-Specific Sphingolipid Metabolism in the Kidneys of Sphingomyelin Synthase 2-Deficient Mice Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD/AFLD-Associated Liver Disease Ceramide Synthase 6 Is a Novel Target of Methotrexate Mediating Its Antiproliferative Effect in a p53-Dependent Manner Sphingolipids and phospholipids in insulin resistance and related metabolic disorders.Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner.Development and validation of an HPLC-MS method for the simultaneous quantification of key oxysterols, endocannabinoids, and ceramides: variations in metabolic syndrome.Efficacy of nutritional interventions to lower circulating ceramides in young adults: FRUVEDomic pilot study Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis.C16:0-ceramide signals insulin resistance Dietary Very Long Chain Saturated Fatty Acids and Metabolic Factors: Findings from the Korea National Health and Nutrition Examination Survey 2013.Fish oil and krill oil differentially modify the liver and brain lipidome when fed to mice.Alterations of the Lipid Metabolome in Dairy Cows Experiencing Excessive Lipolysis Early Postpartum.Liver Perilipin 5 Expression Worsens Hepatosteatosis But Not Insulin Resistance in High Fat-Fed Mice.Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo.An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice.Temporal changes in sphingolipids and systemic insulin sensitivity during the transition from gestation to lactation Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction Glycosphingolipids and cell death: one aim, many ways The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux Targeted Lipidomic and Transcriptomic Analysis Identifies Dysregulated Renal Ceramide Metabolism in a Mouse Model of Diabetic Kidney Disease Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.Fenretinide mediated retinoic acid receptor signalling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function and nutrient stress signalling in adipocytes and adipose tissue.Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.Sphingosine-1-phosphate Phosphatase 2 Regulates Pancreatic Islet β-Cell Endoplasmic Reticulum Stress and Proliferation.Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis.Oxidative stress and calcium dysregulation by palmitate in type 2 diabetes.Plasma Ceramides, Mediterranean Diet, and Incident Cardiovascular Disease in the PREDIMED Trial (Prevención con Dieta Mediterránea).Targeting sphingolipid metabolism in the treatment of obesity/type 2 diabetes.Role of sphingomyelinases in neurological disorders.Regulation of very-long acyl chain ceramide synthesis by acyl-CoA-binding protein.A Role for Ceramides, but Not Sphingomyelins, as Antagonists of Insulin Signaling and Mitochondrial Metabolism in C2C12 Myotubes.Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance.Nuclear Drosophila CerS Schlank regulates lipid homeostasis via the homeodomain, independent of the lag1p motif.Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis.Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?

P2860

Q26739957-658D4059-F811-4B5A-A98F-90D61EC4B21F Q26773230-0F2A15F2-5ADF-4855-8BF6-24CF29E54213 Q28067617-E525D336-BEAB-4304-9816-021F05D0ECD0 Q28073169-7272227E-C809-4E1B-97CB-6A6EFBA13759 Q28547365-00CF8CDF-A3D1-45F8-9578-641239A4FC2F Q28550974-804C9FEF-E4F4-4115-8BC2-D623705BBD77 Q28551941-7FEA2BF4-4E1F-4B28-B020-913D9D3A2870 Q28552611-A382EEC0-98C8-46A3-924F-4BBFEFDC3C64 Q30241943-C67CC64F-14FA-493E-87C5-590AC71EC031 Q30701525-C7B2113E-D2B5-42D7-AEE9-F47C5C6A76E8 Q33466544-667124CE-D1D1-4641-9F8B-638302B2FBE3 Q33896092-E300D63D-32BA-434E-AF3B-98DF3159BC5A Q34485836-29FA21BC-307D-4CE2-950E-8F01A059F30B Q35362267-FDABE1EE-A67A-416E-B94D-FF1D7FAD2D8D Q35916925-9A266FA4-25F9-4408-9CF0-DCF6EF152237 Q35938274-EF1D56F3-5AD1-4383-BCA3-00C5EE0C20E2 Q36068996-E27F5022-E31C-4418-B643-74A2EA4F09CE Q36107299-9EA75E9B-0879-4BAD-B5CA-AD2B3CD03A91 Q36186252-CA49DF92-4C5D-4C2A-86D7-E7098D608E70 Q36287039-18625AB2-B9C2-4D91-AC35-8DEDDB8B2B81 Q36366979-C027B3A4-7A9A-4F86-AB9E-40556CD53514 Q36379436-BFD1466F-BF3E-420B-B086-9E35E3C9397C Q36405917-9160966E-C847-46C3-B94E-0787A50904E5 Q36430696-14DB0240-6794-428C-826E-B6C887382D85 Q36462205-87D85EED-6303-45B7-997E-6B6FD70622CE Q36561524-D7A435D8-876A-4000-A88C-CDC395926015 Q36604243-46027CE8-2396-4924-89E4-53C3F1E29DDA Q37057113-31D90E4C-8C9D-43C9-8667-51FBB886682D Q37065970-FC41ADFA-461C-4239-9B56-9DCA087F2795 Q37662940-DC950A70-DAF5-49D6-9387-2AF0453316BF Q37680068-2C43F0CD-B730-48F9-B6F9-F4C698C72B01 Q38379623-012D617D-D020-42C9-BF8B-9D6087384EDD Q38392764-1F30F654-FBCA-4FE8-965A-D5B59218D005 Q38560939-91B6FB52-C49E-4BD7-A607-80FA7E109525 Q38711466-C3B700AE-8836-4059-8A66-47F73818E383 Q38739901-85571469-09BA-48E3-AFEC-3D3F3E3A0DD5 Q38760082-2B8FDFB6-9BA8-4295-AB99-5BCE074E0477 Q38788263-895D9350-1C11-469C-B52C-5AAB9F3AB394 Q38799232-1690FFDD-F761-4BDC-AE7B-D391F43C5A99 Q38859044-9CDA3A06-EC99-48BF-AD7E-8631C4191CB7

P2860

CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance.

http://www.wikidata.org/entity/Q46828201

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

CerS2 haploinsufficiency inhib ...... atitis and insulin resistance.

@en

CerS2 haploinsufficiency inhib ...... atitis and insulin resistance.

@nl

type

label

CerS2 haploinsufficiency inhib ...... atitis and insulin resistance.

@en

CerS2 haploinsufficiency inhib ...... atitis and insulin resistance.

@nl

prefLabel

CerS2 haploinsufficiency inhib ...... atitis and insulin resistance.

@en

CerS2 haploinsufficiency inhib ...... atitis and insulin resistance.

@nl

P1433

Q46828201-A15A3F60-B757-4372-8CA4-7F4D32AD4850

P1476

Q46828201-48315DA2-5FCD-486E-BD5A-C34DEEF87949

P2093

Q46828201-117263F2-8D79-492E-9901-F988AA6E0315

Q46828201-27F6BD88-6C12-4570-8DD2-4F3F35F49CCC

Q46828201-2A93DED6-3489-448D-9EB5-5741F33FB8A3

Q46828201-2F3ED231-A000-4573-996C-6E698C683371

Q46828201-639F808B-8F9C-45BC-8921-799365A0A1C9

Q46828201-6687C71F-9194-40D9-A117-CC98C93D2BBE

Q46828201-692756B9-3FE6-4815-86FA-EA14ABC973C4

Q46828201-9CEB7496-5951-4217-AEE6-6B5205BA21AA

Q46828201-C4FC6691-AAFB-4CB1-8A15-B7C76FC873B3

Q46828201-C9148360-3A03-4B83-932E-2ACB7D9557A7

P304

Q46828201-897C1D4A-A0B7-41F2-AC2D-7B6363BFBD25

P31

Q46828201-C71C5439-641F-4E2A-A9EF-C96E8298157A

P356

Q46828201-56CE4379-15C7-4349-A1C6-F3B4B846BD7B

P433

Q46828201-C75DB3D7-DD4A-45C8-B2DF-0BC69943A480

P478

Q46828201-681AFEC5-5D0F-4213-B578-944B4E6AE3D7

P50

Q46828201-143CD941-7957-48B0-9B27-1B4AAB247C1E

Q46828201-A82AB602-44DF-4444-93A6-BE882E2F3C7D

P577

Q46828201-14477904-3B33-4011-BEC3-98D0A7FA01A2

P698

Q46828201-5BB8DAA2-651D-427D-BB47-CBCE82EE6D1B

P921

Q46828201-724AAECE-F6D6-4E5E-86B4-CC9458DAB8BC

Q46828201-780A0EC8-5E84-45BC-803B-F2AE1021AF1F

Q46828201-A3017AEF-F002-44E0-940E-9156D6B304BC

P356

J.CMET.2014.09.015

P1433

Cell Metabolism

P1476

CerS2 haploinsufficiency inhib ...... atitis and insulin resistance.

@en

P2093

Bhagirath Chaurasia

http://www.w3.org/2001/XMLSchema#string

Jianhong Ching

http://www.w3.org/2001/XMLSchema#string

Kosuke Takeda

http://www.w3.org/2001/XMLSchema#string

Puck Wee Chan

http://www.w3.org/2001/XMLSchema#string

Scott A Summers

http://www.w3.org/2001/XMLSchema#string

Shaillay Dogra

http://www.w3.org/2001/XMLSchema#string

Shigeki Sugii

http://www.w3.org/2001/XMLSchema#string

Siew Tein Wang

http://www.w3.org/2001/XMLSchema#string

Suryaprakash Raichur

http://www.w3.org/2001/XMLSchema#string

Yael Pewzner-Jung

http://www.w3.org/2001/XMLSchema#string

P304

687-695

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CMET.2014.09.015

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Anthony H. Futerman

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25295789

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

haploinsufficiency